Replimune Group Stock Buy Hold or Sell Recommendation
| REPL Stock | USD 11.66 0.20 1.69% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Replimune Group is 'Hold'. The recommendation algorithm takes into account all of Replimune's available fundamental, technical, and predictive indicators you will find on this site.
Check out Replimune Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Replimune and provide practical buy, sell, or hold advice based on investors' constraints. Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Replimune |
Execute Replimune Buy or Sell Advice
The Replimune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Replimune Group. Macroaxis does not own or have any residual interests in Replimune Group or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Replimune's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Replimune Trading Alerts and Improvement Suggestions
| Replimune Group generated a negative expected return over the last 90 days | |
| Replimune Group has high historical volatility and very poor performance | |
| Net Loss for the year was (215.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (185.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01. | |
| Replimune Group has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Insider Trading |
Replimune Returns Distribution Density
The distribution of Replimune's historical returns is an attempt to chart the uncertainty of Replimune's future price movements. The chart of the probability distribution of Replimune daily returns describes the distribution of returns around its average expected value. We use Replimune Group price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Replimune returns is essential to provide solid investment advice for Replimune.
| Mean Return | -0.1 | Value At Risk | -4.75 | Potential Upside | 5.86 | Standard Deviation | 3.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Replimune historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Replimune Stock Institutional Investors
| Shares | Boxer Capital Management, Llc | 2024-12-31 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Braidwell Lp | 2024-12-31 | 1.5 M | Geode Capital Management, Llc | 2024-12-31 | 1.4 M | Millennium Management Llc | 2024-12-31 | 1.2 M | Wellington Management Company Llp | 2024-12-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1 M | D. E. Shaw & Co Lp | 2024-12-31 | 972.6 K | Mpm Oncology Impact Management Lp | 2024-12-31 | 950 K | Baker Bros Advisors Lp | 2024-12-31 | 11 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 11 M |
Replimune Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (186.4M) | 530K | (142.5M) | 97.2M | 111.8M | 117.4M | |
| Change In Cash | 123.0M | (76.6M) | 40.6M | (72.1M) | (64.9M) | (61.6M) | |
| Free Cash Flow | (63.8M) | (84.5M) | (130.3M) | (191.1M) | (172.0M) | (163.4M) | |
| Depreciation | 1.7M | 2.1M | 2.4M | 2.7M | 3.1M | 3.2M | |
| Other Non Cash Items | 181K | 2.2M | 494K | (11.9M) | (10.7M) | (10.2M) | |
| Capital Expenditures | 2.4M | 2.3M | 2.3M | 5.7M | 6.5M | 6.8M | |
| Net Income | (80.9M) | (118.0M) | (174.3M) | (215.8M) | (194.2M) | (184.5M) | |
| End Period Cash Flow | 184.2M | 107.6M | 148.2M | 76.2M | 87.6M | 88.3M | |
| Change To Netincome | 8.3M | 7.9M | 12.9M | 26.5M | 30.4M | 32.0M | |
| Change To Inventory | 628K | (325K) | 247K | 61K | 54.9K | 52.2K |
Replimune Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Replimune or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Replimune's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Replimune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 1.48 | |
σ | Overall volatility | 3.97 | |
Ir | Information ratio | -0.0008 |
Replimune Volatility Alert
Replimune Group exhibits very low volatility with skewness of 1.54 and kurtosis of 4.81. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Replimune's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Replimune's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Replimune Fundamentals Vs Peers
Comparing Replimune's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Replimune's direct or indirect competition across all of the common fundamentals between Replimune and the related equities. This way, we can detect undervalued stocks with similar characteristics as Replimune or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Replimune's fundamental indicators could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Replimune to competition |
| Fundamentals | Replimune | Peer Average |
| Return On Equity | -0.5 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Current Valuation | 437.11 M | 16.62 B |
| Shares Outstanding | 77.01 M | 571.82 M |
| Shares Owned By Insiders | 4.17 % | 10.09 % |
| Shares Owned By Institutions | 95.83 % | 39.21 % |
| Number Of Shares Shorted | 9.08 M | 4.71 M |
| Price To Book | 1.86 X | 9.51 X |
| EBITDA | (230.2 M) | 3.9 B |
| Net Income | (215.79 M) | 570.98 M |
| Cash And Equivalents | 395.08 M | 2.7 B |
| Cash Per Share | 8.01 X | 5.01 X |
| Total Debt | 75.87 M | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 19.79 X | 2.16 X |
| Book Value Per Share | 6.26 X | 1.93 K |
| Cash Flow From Operations | (185.47 M) | 971.22 M |
| Short Ratio | 14.69 X | 4.00 X |
| Earnings Per Share | (3.07) X | 3.12 X |
| Target Price | 21.13 | |
| Number Of Employees | 331 | 18.84 K |
| Beta | 1.31 | -0.15 |
| Market Capitalization | 897.61 M | 19.03 B |
| Total Asset | 487.72 M | 29.47 B |
| Retained Earnings | (701.28 M) | 9.33 B |
| Working Capital | 393.23 M | 1.48 B |
| Net Asset | 487.72 M |
Note: Acquisition by Andrew Schwendenman of 17775 shares of Replimune subject to Rule 16b-3 [view details]
Replimune Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Replimune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Replimune Buy or Sell Advice
When is the right time to buy or sell Replimune Group? Buying financial instruments such as Replimune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Replimune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Replimune Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.